Dan Mangan is a reporter covering health care and other issues for CNBC.com.
Mangan has been a journalist for more than 20 years, most recently as a general assignment/rewrite reporter at the New York Post. In his more than dozen years at The Post, Mangan routinely covered major stories, including the 9/11 terror attacks, the Bernard Madoff Ponzi scheme, the 2008 financial meltdown and a slew of juicy Gotham scandals du jour, among them the personal tribulations of Yankee slugger Alex Rodriguez.
Prior to that, Mangan began his career in his native Connecticut, writing obituaries for The Hour of Norwalk, before moving on to cover business, government and the court systems at The Hour, the Fairfield County Business Journal and The Advocate of Stamford.
The move gives insurers some protection if a Republican bill to replace Obamacare becomes law.
Republican leaders have repeatedly tried to change the bill since an aborted vote last month.
Trump's ire seems to have been ignited by Democratic threats to oppose a shutdown-avoiding bill if it does not include Obamacare subsidies.
Shkreli is accused of defrauding his former drug company out of millions to pay back hedge-fund investors he allegedly ripped off.
EpiPen's seller Mylan drew criticism last summer for having hiked its price by more than 500 percent over the past decade.
The federal judiciary has been a thorn in President Trump's side over his travel ban, and it could become a counterweight to his power.
Ending $10 billion in payments for cost-sharing assistance would lead to the U.S. to pay out more $12 billion in other subsidies.
The notorious pharma bro Shkreli denies claims he looted a drug company he founded to pay off hedge fund investors he allegedly defrauded.
Groups that support, and oppose, Obamacare are targeting certain GOP lawmakers for pressure as a Republican bill remains stalled.
Shkreli, who gained notoriety for raising the price of a drug by more than 5,000 percent, is accused of ripping off a pharma company he led.